About
MGB Biopharma develops a novel class of antibacterial drugs based on Minor Groove Binder compounds, with a lead candidate, MGB-BP-3, targeting Clostridium difficile infections and demonstrating successful outcomes in Phase IIa clinical trials.
Explore MGB Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.